Resources
Explore our media section to discover insightful videos, informative podcasts, and engaging articles showcasing the innovative applications and advancements in lentiviral vector and RNA delivery tool.
Flash BioSolutions launches GMP production of revolutionary mRNA technology for next-generation vaccines and therapies
Flash BioSolutions increases Gene Delivery RUO production capacity in France to meet surging demand for C2 and C3 GMO-Level Viral Particles
Flash BioSolutions welcomes Stewart Craig to its esteemed Scientific Advisory Board
Flash BioSolutions appoints Anne DEFLISQUE Business & Marketing Director to boost growth
Collaboration between CEA and Flash BioSolutions for the development of cutaneous cell therapy
Flash BioSolutions obtains Pharmaceutical Establishment status, opening up new avenues for its revolutionary FlashRNA® technology
KIRAGEN Bio & Flash BioSolutions announce innovative partnership to revolutionize CAR-T Therapies for solid tumors
Introducing Flash BioSolutions : Spearheading advancements in Biopharmaceutical CDMO sector
Appointment of Jérôme Bédier as Président to accelerate its biopharmaceutical CDMO business development
FAQ
Explore our media section to discover insightful videos, informative podcasts, and engaging articles showcasing the innovative applications and advancements in cell testing technology.
How do Flash BioSolutions lentiviral vectors differ to those from other providers?
Flash BioSolutions has developed a proprietary purification & concentration process for lentiviral vectors production. Purification levels are tailored to your application.
Flash BioSolutions generates high titer and highly pure lentiviral particles that guarantee cell viability and phenotype. Our technical experts are dedicated to the success of your project, from cassette design to transduction protocols.
What are the differences between AAV and Lentiviral vectors?
Each method has both advantages and drawbacks for specific applications, depending on its technical characteristics. For example, the use of AAVs for the transfer of genetic material is limited by the length of the sequence of interest and by the pseudotype; non-viral methods can be problematic for the study of gene expression in primary cells because of cell toxicity and/or lower efficiency.
CONTACT US
We invite you to reach out to us for any inquiries regarding our services, technical support, or potential collaborations.
Please complete the following form, and a member of our team will respond promptly.
+33(0) 5 61 28 70 75